JP6802185B2 - ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 - Google Patents
ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 Download PDFInfo
- Publication number
- JP6802185B2 JP6802185B2 JP2017555780A JP2017555780A JP6802185B2 JP 6802185 B2 JP6802185 B2 JP 6802185B2 JP 2017555780 A JP2017555780 A JP 2017555780A JP 2017555780 A JP2017555780 A JP 2017555780A JP 6802185 B2 JP6802185 B2 JP 6802185B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- buffer
- peptide
- profiling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153475P | 2015-04-27 | 2015-04-27 | |
| US62/153,475 | 2015-04-27 | ||
| PCT/US2016/029495 WO2016176288A1 (en) | 2015-04-27 | 2016-04-27 | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514210A JP2018514210A (ja) | 2018-06-07 |
| JP2018514210A5 JP2018514210A5 (enExample) | 2019-07-04 |
| JP6802185B2 true JP6802185B2 (ja) | 2020-12-16 |
Family
ID=57198812
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20180120297A1 (enExample) |
| EP (2) | EP3289094B1 (enExample) |
| JP (3) | JP6802185B2 (enExample) |
| AU (2) | AU2016253957C1 (enExample) |
| CA (1) | CA2983022C (enExample) |
| WO (2) | WO2016176288A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2496400A1 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| CA2645853A1 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| EP2898327A1 (en) * | 2012-09-19 | 2015-07-29 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| HK1247250A1 (zh) | 2015-01-12 | 2018-09-21 | Eutropics Pharmaceuticals, Inc. | 用於指导癌症治疗的内容相关的诊断测试 |
| AU2016232833A1 (en) | 2015-03-18 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Selective Mcl-1 binding peptides |
| MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| PL3298021T3 (pl) | 2015-05-18 | 2019-11-29 | Tolero Pharmaceuticals Inc | Proleki alvocidibu o zwiększonej biodostępności |
| MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
| US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| WO2018119000A1 (en) * | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US11286299B2 (en) | 2018-09-17 | 2022-03-29 | Massachusetts Institute Of Technology | Peptides selective for Bcl-2 family proteins |
| AU2019391097B2 (en) | 2018-12-04 | 2025-07-03 | Sumitomo Pharma America, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| JP7589159B2 (ja) * | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| BR9610058A (pt) | 1995-07-28 | 1999-07-27 | Marie Curie Cancer Care | Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células |
| JP3295431B2 (ja) | 1995-10-24 | 2002-06-24 | サングスタット メディカル コーポレイション | 抗アルファ−ガラクトシルスクリーニング技術 |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| JP2001524301A (ja) | 1997-09-17 | 2001-12-04 | ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ | 新規治療用分子 |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| EP1210098A1 (en) | 1999-04-07 | 2002-06-05 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| AU6906100A (en) | 1999-08-16 | 2001-03-13 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| US20020115613A1 (en) | 2001-02-16 | 2002-08-22 | Kumar M. Vijay | Treatment of prostate cancer |
| WO2003040168A2 (en) | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| WO2003055515A1 (en) | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| CA2496400A1 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| KR20050119128A (ko) * | 2003-03-19 | 2005-12-20 | 알파 와슬만, 인크. | 세포내 성분, 및 그로부터 유래된 단백질의 분리 및 축적 |
| SI1680443T1 (sl) | 2003-11-05 | 2014-01-31 | Dana-Farber Cancer Institute, Inc. | Stabilizirani peptidi z alfa vijačnico in uporabe le-teh |
| US7714005B2 (en) | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
| JP2005130867A (ja) * | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| WO2007016254A2 (en) | 2005-07-27 | 2007-02-08 | The Board Of Trustees Of The University Of Arkansas | Antineoplastic activities of ellipticine and its derivatives |
| CA2645853A1 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) * | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| WO2008021484A2 (en) | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| EP2200653A2 (en) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Mitochondria-targeted anti-tumour agents |
| EP2208061B1 (en) * | 2007-09-26 | 2017-11-08 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| JP2009240173A (ja) * | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| US8535944B2 (en) * | 2009-06-11 | 2013-09-17 | Minerva Biotechnologies Corporation | Culturing embryonic stem cells, embryonic stem-like cells, or induced pluripotent stem cells with a Muc1 or Muc1* ligand |
| WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) * | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| KR102062416B1 (ko) * | 2012-05-10 | 2020-01-03 | 유트로픽스 파마슈티컬스, 인크. | 실용 가능한 암 진단 대체 법 |
| WO2013188978A1 (en) | 2012-06-20 | 2013-12-27 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| EP2898327A1 (en) | 2012-09-19 | 2015-07-29 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
| JP6327662B2 (ja) * | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| WO2015010094A1 (en) * | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| CA2922503C (en) * | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| US11092602B2 (en) | 2015-07-06 | 2021-08-17 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| JP7589159B2 (ja) | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
-
2016
- 2016-04-27 EP EP16787045.0A patent/EP3289094B1/en active Active
- 2016-04-27 WO PCT/US2016/029495 patent/WO2016176288A1/en not_active Ceased
- 2016-04-27 WO PCT/US2016/029510 patent/WO2016176299A1/en not_active Ceased
- 2016-04-27 JP JP2017555780A patent/JP6802185B2/ja active Active
- 2016-04-27 JP JP2017555779A patent/JP6814745B2/ja active Active
- 2016-04-27 AU AU2016253957A patent/AU2016253957C1/en active Active
- 2016-04-27 US US15/569,851 patent/US20180120297A1/en not_active Abandoned
- 2016-04-27 EP EP16787039.3A patent/EP3288964B1/en active Active
- 2016-04-27 CA CA2983022A patent/CA2983022C/en active Active
- 2016-04-27 US US15/568,994 patent/US10761086B2/en active Active
- 2016-04-27 AU AU2016255749A patent/AU2016255749B2/en active Active
-
2020
- 2020-07-27 US US16/939,736 patent/US11867688B2/en active Active
- 2020-12-03 JP JP2020200805A patent/JP2021036915A/ja not_active Withdrawn
-
2021
- 2021-02-26 US US17/186,344 patent/US20210255167A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2983024A1 (en) | 2016-11-03 |
| US20180128813A1 (en) | 2018-05-10 |
| EP3289094A1 (en) | 2018-03-07 |
| US20210255167A1 (en) | 2021-08-19 |
| HK1252055A1 (en) | 2019-05-10 |
| JP2021036915A (ja) | 2021-03-11 |
| CA2983022C (en) | 2023-03-07 |
| EP3289094A4 (en) | 2018-10-31 |
| EP3289094B1 (en) | 2024-06-05 |
| AU2016253957A1 (en) | 2017-10-19 |
| US11867688B2 (en) | 2024-01-09 |
| EP3288964B1 (en) | 2024-02-21 |
| AU2016253957C1 (en) | 2021-04-01 |
| AU2016253957B2 (en) | 2020-10-22 |
| WO2016176299A1 (en) | 2016-11-03 |
| CA2983022A1 (en) | 2016-11-03 |
| HK1252058A1 (en) | 2019-05-10 |
| US20210041419A1 (en) | 2021-02-11 |
| JP2018514210A (ja) | 2018-06-07 |
| US10761086B2 (en) | 2020-09-01 |
| AU2016255749B2 (en) | 2021-10-14 |
| EP3288964A1 (en) | 2018-03-07 |
| US20180120297A1 (en) | 2018-05-03 |
| EP3288964A4 (en) | 2018-10-31 |
| AU2016255749A1 (en) | 2017-10-19 |
| JP2018520638A (ja) | 2018-08-02 |
| WO2016176288A1 (en) | 2016-11-03 |
| JP6814745B2 (ja) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6802185B2 (ja) | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 | |
| EP2660601B1 (en) | Methods for detecting molecular interactions | |
| Mendes et al. | Optimization of the magnetic recovery of hits from one-bead–one-compound library screens | |
| KR20030094404A (ko) | 프로테옴 칩을 사용한 단백질 활성의 포괄적인 분석 | |
| US20220163510A1 (en) | Live cell imaging dynamic bh3 profiling | |
| Doran et al. | A liquid array platform for the multiplexed analysis of synthetic molecule–protein interactions | |
| CN112964881A (zh) | 一种高通量高灵敏度的单细胞转染蛋白质分析芯片 | |
| WO2007130549A1 (en) | Monoclonal antibody microarray | |
| Head et al. | Identification of small molecule-binding proteins in a native cellular environment by live-cell photoaffinity labeling | |
| KR101580360B1 (ko) | 연자성미세구조물을 이용한 리간드의 스크리닝 시스템 및 그 용도 | |
| Guise et al. | Approaches for studying the subcellular localization, interactions, and regulation of histone deacetylase 5 (HDAC5) | |
| Rees et al. | Identification of the cis-molecular neighbours of the immune checkpoint protein B7-H4 in the breast cancer cell-line SK-BR-3 by proteomic proximity labelling | |
| HK1252058B (en) | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells | |
| KR101444995B1 (ko) | 세포질 단백질의 단백질-단백질 상호작용을 확인하는 방법 | |
| CA2983024C (en) | Compositions and methods for assessing toxicity using dynamic bh3 profiling | |
| JP2009250652A (ja) | 細胞内移行性速度を測定することによる機能性物質のスクリーニング法 | |
| Clausen | Guidelines for mouse and human DC functional assays | |
| HK1252055B (en) | Compositions and methods for assessing toxicity using dynamic bh3 profiling | |
| Diamante et al. | Bead surface display for affinity screening of protein and peptide binders | |
| WO2015007383A1 (en) | Solid phase transfection of proteins and nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190529 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201111 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201126 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6802185 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |